Given the robust oncology, neuroscience and rare disease portfolio, the financial targets for FY22 seem attainable in our view. Somatuline, despite the entry of generics, Dysport, Cabometyx and Onivyde would be the primary top-line growth contributors and margin expansion would be driven by increasing synergies from the commercial infrastructure. Management has upped its investments into R&D to ensure sustained growth in the long term.
20 May 2019
Mid-term targets within reach; R&D pipeline robust
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Mid-term targets within reach; R&D pipeline robust
Ipsen SA (IPN:WBO) | 0 0 5.0% | Mkt Cap: 10,144m
- Published:
20 May 2019 -
Author:
Sumit Sayal -
Pages:
4
Given the robust oncology, neuroscience and rare disease portfolio, the financial targets for FY22 seem attainable in our view. Somatuline, despite the entry of generics, Dysport, Cabometyx and Onivyde would be the primary top-line growth contributors and margin expansion would be driven by increasing synergies from the commercial infrastructure. Management has upped its investments into R&D to ensure sustained growth in the long term.